TR115 treatment for advanced tumors with ARID1A mutation
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests an investigational drug called TR115 for people with advanced solid tumors that have a specific genetic change called ARID1A. It may help if standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- Your cancer is advanced and has a change in the ARID1A gene.
- You have one of these cancer types: clear cell ovarian, fallopian tube, or peritoneal cancer that is resistant to platinum; endometrial cancer that progressed after platinum and immunotherapy; or other advanced solid tumors (like stomach or bladder cancer) that progressed after standard treatment.
- You are able to perform daily activities with mild or no help (ECOG score 0-1) and have a life expectancy of at least 3 months.
- Your organs are working well enough (blood counts, liver, kidney, heart) and you have no brain metastases.
- You can provide a tumor tissue sample (fresh or stored) for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.
This trial tests a new combination treatment for people with advanced solid tumors that have not responded to standard therapy. It aims to find a safe dose and see if the combination can shrink tumors.
This trial tests a new drug called Trastuzumab Rezetecan in people with advanced solid tumors that are HER2-positive and have not responded to standard therapies. It includes three specific groups: people with extramammary Paget's disease, rare solid tumors, or urothelial carcinoma. The goal is to see if this drug can shrink tumors or slow their growth.
This early-phase trial studies TR64 in people with advanced solid cancers when standard treatments have stopped working or aren’t an option. It aims to see whether the drug can reduce tumors and is safe enough to keep studying.
This trial tests an experimental drug called TR115 versus your doctor's choice of standard treatment for peripheral T-cell lymphoma that has come back or stopped responding to prior treatments. TR115 may help control this rare blood cancer by targeting specific cancer pathways.
This study tests an experimental drug, BR113, for people whose cancer has spread and not responded to standard treatments. It may offer a new option for those with advanced solid tumors, and the trial helps determine if the drug is safe and effective.
Hear when a new Ovarian Clear Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.